Replies to post #3800 on Biotech Values

[DewDiligence]

>> If increasing the # of pts meant adding centers, it could explain part of the delay. <<

Possibly, but we’re talking about only 15 additional patients. The reason for running multiple sites in a phase-2 trial is to speed enrollment; hence, holding up a trial in order to add sites is counterintuitive.